Europe Enteral Feeding Market

Increasing incidence of preterm births

For preterm newborns, enteral feeding is the recommended mode of nutrition delivery. Even yet, parenteral nourishment is still a viable option for post term delivery nutrition needs. Furthermore, enteral feeding continues to offer substantial non-nutritional and nutritional advantages. Furthermore, the European Commission reports that the number of premature births in Europe is increasing, with an estimated 500,000 births occurring each year. This is because women are having children later in life, suffering from obesity and diabetes at higher rates, and having more children as a result of reproductive treatments.

These infants have an increased risk of both acute and chronic health problems, including learning impairments, respiratory infections, and mobility difficulties like cerebral palsy.

Furthermore, infants born with genetic disorders, such as congenital genetic disorders and rare diseases like Prader-Willi Syndrome, necessitate enteral feeding via tubes. As a result, rising demand for enteral feeding therapies in neonates and infants is propelling revenue growth in the European enteral feeding market.

Europe Enteral Feeding Market 

The demographic shift towards an aging population in Europe significantly influences the Global Europe Enteral Feeding Market Industry. Older adults are more susceptible to health issues that may impair their ability to consume food orally, thus increasing reliance on enteral feeding methods. According to Eurostat, the proportion of individuals aged 65 and over is projected to rise, which correlates with a higher demand for enteral nutrition products. This demographic trend is likely to propel the market towards an estimated value of 5200 USD Million by 2035, highlighting the importance of catering to this growing segment.

The Global Europe Enteral Feeding Market Industry benefits from supportive regulatory frameworks that facilitate the approval and availability of enteral nutrition products. Regulatory bodies in Europe, such as the European Food Safety Authority, ensure that enteral feeding products meet safety and efficacy standards. This regulatory support fosters innovation and encourages manufacturers to develop new products that cater to diverse patient needs. As a result, the market is likely to experience sustained growth, with an anticipated valuation of 3500 USD Million in 2024, driven by the continuous introduction of compliant and effective solutions.

Growing awareness and education regarding the benefits of enteral feeding among healthcare professionals and patients are driving the Global Europe Enteral Feeding Market Industry. Initiatives by healthcare organizations to promote enteral nutrition as a viable option for patients unable to eat orally have led to improved acceptance and utilization. This increased awareness is likely to enhance market growth, as more healthcare providers recognize the importance of nutritional support in patient care. Consequently, the market is poised for expansion, aligning with the projected growth trajectory towards 5200 USD Million by 2035.

The Global Europe Enteral Feeding Market Industry experiences growth driven by the increasing prevalence of chronic diseases such as cancer, neurological disorders, and gastrointestinal diseases. These conditions often necessitate enteral feeding as a means of nutritional support. For instance, the European Cancer Information System indicates that cancer cases are projected to rise, leading to a higher demand for enteral nutrition solutions. This trend is expected to contribute to the market's valuation, which is estimated to reach 3500 USD Million in 2024, reflecting a growing need for effective nutritional interventions.

Innovations in enteral feeding devices and delivery systems are pivotal in shaping the Global Europe Enteral Feeding Market Industry. The introduction of smart feeding pumps and advanced nutritional formulations enhances patient compliance and outcomes. For example, the development of devices that allow for remote monitoring and adjustments can significantly improve the management of enteral feeding. As these technologies become more prevalent, they are expected to contribute to a compound annual growth rate of 3.66% from 2025 to 2035, reflecting the market's adaptability to evolving healthcare needs.

The Europe enteral feeding market is distinguished by the presence of numerous Europe, regional, and local players catering to the enteral feeding techniques that are evolving at a rapid pace. Furthermore, the increasing incidence of preterm births is further driving the growth of Europe enteral feeding market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs.

Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new software and services.

Fresenius Kabi AG is a pharmaceutical company with a wide portfolio that includes intravenously administered drugs, infusion therapy, clinical nutrition, medical devices, and transfusion technology. Its product portfolio also comprises a comprehensive range of I.V. generic drugs, infusion therapies, clinical nutrition products, and the medical devices for administering these products.

Moreover in march 2022 Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. (“mAbxience”), a leading international biopharmaceutical company